AstraZeneca PLC vs Amgen Inc.: A Gross Profit Performance Breakdown

AstraZeneca vs Amgen: A Decade of Gross Profit Performance

In the competitive landscape of the pharmaceutical industry, AstraZeneca PLC and Amgen Inc. have showcased remarkable financial trajectories over the past decade. From 2014 to 2023, AstraZeneca's gross profit surged by approximately 87%, peaking at $37.77 billion in 2023. This growth reflects AstraZeneca's strategic innovations and market expansions. Meanwhile, Amgen demonstrated steady growth, with a 26% increase in gross profit, reaching nearly $19.98 billion in 2022. Notably, AstraZeneca's gross profit consistently outpaced Amgen's, particularly from 2020 onwards, highlighting its robust market positioning. The data underscores the dynamic shifts within the pharmaceutical sector, driven by research advancements and global health demands. As these giants continue to evolve, their financial performances offer valuable insights into the industry's future direction.